Skip to main content

Jazz Pharmaceuticals PLC (JAZZ)

NASDAQ: JAZZ · IEX Real-Time Price · USD
144.14 -1.53 (-1.05%)
Oct 21, 2021 4:00 PM EDT - Market closed
Market Cap8.84B
Revenue (ttm)2.63B
Net Income (ttm)40.16M
Shares Out61.36M
EPS (ttm)0.69
PE Ratio209.51
Forward PE7.98
Dividendn/a
Ex-Dividend Daten/a
Volume295,601
Open145.10
Previous Close145.67
Day's Range143.00 - 146.42
52-Week Range126.01 - 189.00
Beta0.95
AnalystsBuy
Price Target205.47 (+42.5%)
Est. Earnings DateNov 1, 2021

About JAZZ

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narc...

IndustryPharmaceuticals
IPO DateJun 1, 2007
Employees1,940
Stock ExchangeNASDAQ
Ticker SymbolJAZZ
Full Company Profile

Financial Performance

In 2020, JAZZ's revenue was $2.36 billion, an increase of 9.34% compared to the previous year's $2.16 billion. Earnings were $238.62 million, a decrease of -54.41%.

Financial Statements

Analyst Forecast

According to 20 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is 205.47, which is an increase of 42.55% from the latest price.

Price Target
$205.47
(42.55% upside)
Analyst Consensus: Buy

News

Best Marijuana Stocks To Watch For Your Long Term Portfolio Right Now

Is Now The Time To Add To Your Long Term Portfolio? The post Best Marijuana Stocks To Watch For Your Long Term Portfolio Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roo...

Other symbols:IIPR
1 week ago - MarijuanaStocks

SEC Charges Former Goldman Sachs Officer For Insider Trading On 2 M&A Deals

The Securities and Exchange Commission has charged a former Goldman Sachs (NYSE: GS) compliance analyst with using confidential information to generate over $471,000 in ill-gotten gains. The suit allege...

2 weeks ago - Benzinga

September Sell-Off: 3 Dirt Cheap Growth Stocks to Buy

Get these stocks while they're near their 52-week lows.

Other symbols:ATVIBABA
4 weeks ago - The Motley Fool

Are These 2 Top Cannabis Stocks On Your List For September? 2 To Watch For Your Long Term Portfolio

Top Cannabis Stocks To Watch Mid-September The post Are These 2 Top Cannabis Stocks On Your List For September? 2 To Watch For Your Long Term Portfolio appeared first on Marijuana Stocks | Cannabis Inve...

Other symbols:SMG
1 month ago - MarijuanaStocks

Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on Octobe...

DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m.

1 month ago - PRNewsWire

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

DUBLIN, Sept. 8, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will participate in the following upcoming virtual investor conferences: BofA Virtual Globa...

1 month ago - PRNewsWire

2 Marijuana Stocks To Watch At The Beginning Of September 2021

2 Marijuana Stocks To Watch This Month For Better Trading The post 2 Marijuana Stocks To Watch At The Beginning Of September 2021 appeared first on Marijuana Stocks | Cannabis Investments and News. Root...

Other symbols:SMG
1 month ago - MarijuanaStocks

3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023

These fast-paced companies should generate jaw-dropping revenue growth over the next three years.

Other symbols:MRNAZGNX
1 month ago - The Motley Fool

Jazz (JAZZ) Down 14.1% Since Last Earnings Report: Can It Rebound?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

3 Biotech Stocks That Are Too Cheap to Ignore

You'll definitely want to check out these biotech bargains.

Other symbols:ABBVAXSM
1 month ago - The Motley Fool

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – ...

Other symbols:ASNDCARASESNSNY
1 month ago - Benzinga

Canada Approves Jazz Pharma's Excessive Daytime Sleepiness Med

Health Canada has approved Jazz Pharmaceuticals plc's (NASDAQ: JAZZ) Sunosi (solriamfetol) for excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) in adult pat...

1 month ago - Benzinga

Got $4,000? Buy These 2 Cannabis-Focused Biotech Stocks

Neither of them needs to sell marijuana to consumers to succeed.

Other symbols:XXII
1 month ago - The Motley Fool

The Smartest Stocks to Buy With $600 Right Now

Bargains abound, even with the stock market near an all-time high.

Other symbols:PUBMTRUP
1 month ago - The Motley Fool

Best Medical Marijuana Stocks To Buy In 2021? 2 Possible Long Term Investments Right Now

Could These Be Good Long Term Investments For Your Portfolio? The post Best Medical Marijuana Stocks To Buy In 2021? 2 Possible Long Term Investments Right Now appeared first on Marijuana Stocks | Canna...

Other symbols:ABBV
1 month ago - MarijuanaStocks

This Cannabis Stock Is Full of Potential and Hasn't Been This Cheap in Months

Investors have been selling off the stock since the company released its earnings report earlier this month.

2 months ago - The Motley Fool

A Week's Worth of Actionable Cannabis Stock News

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up...

2 months ago - Schaeffers Research

Jazz's (JAZZ) Xywav Gets FDA Nod for Idiopathic Hypersomnia

Jazz's (JAZZ) Xywav gets FDA approval for new indication, idiopathic hypersomnia. Following approval, Xywav becomes the first drug for treatment of this sleep disorder.

2 months ago - Zacks Investment Research

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral ...

DUBLIN, Aug. 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav® (calcium, magnesium, potassium, and sodium ...

2 months ago - PRNewsWire

Jazz's (JAZZ) Epidyolex Gets Approval for New Indication in UK

Jazz's (JAZZ) unit GW Pharmaceuticals' Epidyolex (cannabidiol) gets a regulatory nod for a new indication in the United Kingdom. Following this announcement, stock prices fell.

2 months ago - Zacks Investment Research

Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers

LOS ANGELES, Aug. 10, 2021 /PRNewswire/ -- Stand Up To Cancer® (SU2C) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announce a three-year, $4 million research collaboration to explore new opportunit...

2 months ago - PRNewsWire

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associa...

LONDON, Aug. 10, 2021 /PRNewswire/ -- GW Pharmaceuticals ("GW"), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines and now part of Jazz Pharmaceutical...

2 months ago - PRNewsWire

Your Weekly Hit of Cannabis Stocks on the Move

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up...

2 months ago - Schaeffers Research

Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout

Jazz Pharma's (JAZZ) product revenues grow in the second quarter on the back of strong demand for its new drugs and additional sales from drugs added with the acquisition of GW Pharmaceuticals.

2 months ago - Zacks Investment Research

Jazz Pharmaceuticals (JAZZ) Tops Q2 Earnings and Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 9.86% and 1.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research